Sitaxentan to be Withdrawn Due to Cases of Unpredictable Serious Liver Injury
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Sitaxentan to be Withdrawn Due to Cases of Unpredictable Serious Liver Injury

LONDON -- December 11, 2010 -- The European Medicines Agency has been informed of Pfizer’s decision to voluntarily withdraw sitaentan (Thelin) from the market worldwide further to new information on 2 cases of fatal liver injury. Pfizer has also decided to discontinue all ongoing clinical trials.

Sitaxentan has been authorised in the EU since 2006 for the treatment of pulmonary arterial hypertension.

Sitaxentan has been known to be associated with liver toxicity and since its initial marketing authorisation has been contra-indicated in patients with mild to severe hepatic impairment (Child-Pugh Class A-C) and elevated aminotransferases prior to initiation of treatment.

At this stage, patients taking sitaxentan or participating in sitaxentan studies are advised not to stop treatment and to consult their treating physician to review their treatment at their next scheduled appointment.

The Agency’s scientific Committee for Medicinal Products for Human Use (CHMP) will look at this issue during their plenary meeting December 13-16, 2010, and will provide detailed advice for patients and prescribers.

SOURCE: European Medicines Agency

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities